In June 2024, Valisure leadership met with the FDA CDER's top officials in an in-person discussion to share the company’s evolution and future vision. During this successful dialogue, Valisure emphasized its critical role in advancing pharmaceutical transparency and quality assurance. The meeting provided a forum to highlight the company’s independent testing efforts, groundbreaking research, and commitment to enhancing the pharmaceutical supply chain's quality and reliability.

This dialogue marked an essential step in strengthening collaboration between Valisure and the FDA, as both entities work to address pressing challenges in drug safety and efficacy and the resilience of the US pharmaceutical supply chain.

Valisure remains committed to partnering with regulatory agencies like the FDA to uphold the highest standards in the pharmaceutical industry, reinforcing its position as a leader in independent quality assurance.

‍

In June 2024, Valisure leadership met with the FDA CDER's top officials in an in-person discussion to share the company’s evolution and future vision. During this successful dialogue, Valisure emphasized its critical role in advancing pharmaceutical transparency and quality assurance. The meeting provided a forum to highlight the company’s independent testing efforts, groundbreaking research, and commitment to enhancing the pharmaceutical supply chain's quality and reliability.

This dialogue marked an essential step in strengthening collaboration between Valisure and the FDA, as both entities work to address pressing challenges in drug safety and efficacy and the resilience of the US pharmaceutical supply chain.

Valisure remains committed to partnering with regulatory agencies like the FDA to uphold the highest standards in the pharmaceutical industry, reinforcing its position as a leader in independent quality assurance.

‍